Through this agreement, Icon and Tigermed will collaborate to offer pharmaceutical and biotechnology clients better access to Chinese patients, utilising the global reach and experience of the Icon organisation, complemented by Tigermed’s in depth knowledge of the Chinese drug development landscape and geographic coverage in China.
John Hubbard, group president of global clinical research services at Icon, said: “Tigermed has a substantial clinical operations presence on the Chinese mainland and this experience, gives them the ability to provide wide-ranging support for clinical drug development in China. TigerMed’s strength in China, complements Icon’s strong regional presence in Asia Pacific and makes them the ideal partner for Icon as we continue to drive the rapid and effective development of our client’s global drug development portfolios.”
Xiaoping Ye, chairman and CEO at Tigermed, said: “We are extremely pleased to have signed this agreement with Icon. Not only are Icon recognised as a truly global provider of quality clinical services, their culture and core values built around people, performance and client focus fit well with those of Tigermed. This alliance enhances our regional and global capabilities and will enable both Icon and Tigermed to expand the range of clinical research services we can offer to clients in China and around the globe.”